Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study by Dvorak, C.C. et al.
Disease Burden and Conditioning Regimens in ASCT1221, A 
Randomized Phase II Trial in Children with Juvenile 
Myelomonocytic Leukemia: A Children’s Oncology Group Study
Christopher C. Dvorak,




University of California San Francisco
Mitchell S. Cairo,
Maria Fareri Children’s Hospital, Westchester Medical Center, New York Medical College
Ha Dang,






Hospital for Sick Children
Tali Mazor,
University of California San Francisco
Adam B. Olshen,
University of California San Francisco
Joel S. Parker,





Corresponding Author: Christopher C. Dvorak, M.D., Professor of Clinical Pediatrics, Chief, Division of Pediatric Allergy, 
Immunology & Bone Marrow Transplantation, Benioff Children’s Hospital, University of California San Francisco, 550 16th Street, 
4th Floor, Box 0434, San Francisco, CA 94143, Phone: 415-476-0554, Fax: 415-502-4867, christopher.dvorak@ucsf.edu. 
CONFLICTS OF INTEREST
The authors declare no conflict of interest.
HHS Public Access
Author manuscript
Pediatr Blood Cancer. Author manuscript; available in PMC 2019 July 01.
Published in final edited form as:














St. Jude Children’s Research Hospital
Neil Patel,






Cincinnati Children’s Hospital Medical Center
Stephan A. Grupp, and
Children’s Hospital of Philadelphia
Mignon L. Loh
University of California San Francisco
Abstract
Background—Most patients with juvenile myelomonocytic leukemia (JMML) are curable only 
with allogeneic hematopoietic cell transplantation (HCT). However, the current standard 
conditioning regimen, busulfan-cyclophosphamide-melphalan (Bu-Cy-Mel), may be associated 
with higher risks of morbidity and mortality. ASCT1221 was designed to test whether the 
potentially less-toxic myeloablative conditioning regimen containing busulfan-fludarabine (Bu-
Flu) would be associated with equivalent outcomes.
Procedure—Twenty-seven patients were enrolled on ASCT1221 from 2013–2015. Pre- and 
post-HCT (starting Day +30) mutant allele burden was measured in all and pre-HCT therapy was 
administered according to physician discretion.
Results—Fifteen patients were randomized (6 to Bu-Cy-Mel and 9 to Bu-Flu) after meeting 
diagnostic criteria for JMML. Pre-HCT low-dose chemotherapy did not appear to reduce pre-HCT 
disease burden. Two patients, however, received aggressive chemotherapy pre-HCT and achieved 
low disease-burden state; both are long-term survivors. All 4 patients with detectable mutant allele 
burden at Day +30 post-HCT eventually progressed, as compared to 2 of 9 patients with 
unmeasurable allele burden (p=0.04). The 18-month event-free-survival of the entire cohort was 
47% (95% CI, 21–69%); and was 83% (95% CI, 27–97%) and 22% (95% CI, 03–51%) for Bu-
Cy-Mel and Bu-Flu, respectively (p=0.04). ASCT1221 was terminated early due to concerns that 
the Bu-Flu arm had inferior outcomes.
Conclusions—The regimen of Bu-Flu is inadequate to provide disease control in patients with 
JMML who present to HCT with large burdens of disease. Advances in molecular testing may 
allow better characterization of biologic risk, pre-HCT responses to chemotherapy, and post-HCT 
management.
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INTRODUCTION
Juvenile myelomonocytic leukemia (JMML) is classified as an overlapping 
myeloproliferative/myelodysplastic neoplasm, with a median age of diagnosis of <2 years.1,2 
Patients frequently present with high disease burdens and severe symptoms, including 
massive hepatosplenomegaly, pulmonary infiltrates, fevers, and rash.3 The precise role of 
pre-transplant chemotherapy to attempt to minimize disease-burden is not yet determined.1,4 
The majority of patients are now molecularly diagnosed via identification of mutations in 
PTPN11, NRAS, KRAS, RRAS, RRAS2, CBL, SETBP1, or NF1.5
With few exceptions, long-term event-free survival (EFS) has only been achieved following 
allogeneic hematopoietic cell transplantation (HCT).6 The most common conditioning 
regimen utilized is busulfan, cyclophosphamide, and melphalan (Bu-Cy-Mel).1 Young 
children with JMML are known to be at risk for transplant-related mortality (TRM), with 
reported rates of 10–22% in patients with JMML,1,2,7 Identification of a less-toxic 
conditioning regimen may help improve short- and long-term outcomes. The conditioning 
regimen of busulfan and fludarabine (Bu-Flu) had decreased toxicity and equivalent survival 
compared with the Bu-Cy-Mel regimen in a non-randomized study of patients mainly with 
acute myeloid leukemia (AML) in remission.8 Pharmacokinetic analysis of busulfan 
demonstrated that adding a third alkylating agent increases the risk of acute toxicities, 
including sinusoidal obstruction syndrome (SOS) and graft-versus-host disease (GVHD).9
Here we report the findings of the randomized Phase II Children’s Oncology Group (COG) 
study ASCT1221 in patients with de novo JMML. The objective was to pick the winner of 
two different conditioning regimens on the basis of the one with the lowest risk of TRM, as 
long as EFS was comparable.
METHODS
Eligibility
ASCT1221 (registered at www.clinicaltrials.gov as NCT 01824693) activated in June 2013 
and approved by the National Cancer Institute Central Institutional Review Board (IRB) and 
local center IRBs. Legal guardians signed written informed consent. Patients with suspected 
JMML were eligible for Part 1 of the study to confirm the diagnosis. Central review of 
clinical characteristics, pathology, cytogenetics (including G-banding and interphase FISH 
analysis for monosomy 7), and molecular testing was performed to ensure that patients met 
consensus criteria for JMML10 prior to proceeding to HCT on Part 2 of the study. Patients 
with germline mutations in PTPN11 or who had progressed to AML (>20% blasts) were 
excluded.
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ASCT1221 did not mandate the use of, or a particular approach to, pre-HCT therapy 
(including the potential use of splenectomy), which was left to the discretion of the treating 
physician. The use of pre-HCT chemotherapy was captured and defined as: none, low-dose 
(including treatment with 6-mercaptopurine [6-MP] and/or cis-retinoic acid), or AML-like 
(cytarabine ≥1 g/m2/day +/− other agents).
Conditioning and Transplant
All patients who met eligibility criteria (appropriate donor identified, adequate organ 
function, absence of uncontrolled infection) could proceed to HCT per the treating 
physician. Donor selection was per treating physician and included matched siblings (MSD), 
adult unrelated donors (URD), and umbilical cord blood (UCB), but not haploidentical-
related donors. Allele-level HLA-matching at ≥7/8 loci was required for URD. For UCB, 
≥4/6 serologic HLA-matching at HLA-A and –B (with allele level at HLA-DR), and a dose 
≥5×107 nucleated cells/kg were required. Stratified randomization occurred based on donor 
type and the presence of PTNP11 mutations, which have been considered high-risk.11–13
Conditioning regimen A (Bu-Cy-Mel) was intravenous busulfan (initial 3.2–4 mg/kg/day, 
with 1–2 therapeutic dose adjustments to achieve a cumulative area under the curve [AUC] 
of 59–98 mg*h/L, or 3600–6000 μM/L*Min per day) on Days −8 to −5, cyclophosphamide 
(60 mg/kg/dose with prophylactic mesna 60 mg/kg/day) on Days −4 to −3, and melphalan 
(140 mg/m2, or 4.67 mg/kg for patients <10 kg) on Day −1. Conditioning regimen B (Bu-
Flu) was intravenous busulfan (as above) on Days −8 to −5, and fludarabine (40 mg/m2/
dose, or 1.33 mg/kg/dose for patients <10 kg) on Days −5 to −2. Rabbit anti-thymocyte 
globulin (2 mg/kg/dose) was added to recipients of cells from URD (on Days −4 to −1) or 
UCB (on Days −8 to −5).
GVHD prophylaxis was tacrolimus (starting on Day −1 with goal level of 5–12 ng/mL; taper 
starting by Day +60 and complete by Day +98 for MSD; taper starting by Day +100 and 
complete by Day +180 for URD/UCB), and mycophenolate mofetil (15 mg/kg/dose every 8 
hours; from Day +1 to Day +30 for MSD, or Day +45 for URD/UCB).
Response Criteria and Definitions
Disease response was defined according to international consensus criteria.14 Mutant allele 
burden was measured at diagnosis, prior to HCT and at regular intervals after HCT, with the 
first measurement occurring at Day +30. Primary graft failure was defined as failure to 
achieve an absolute neutrophil count of ≥500/mm3 after 42 days or <5% donor cells in bone 
marrow by Day +42, without evidence of JMML. SOS was defined by the Baltimore criteria.
15 Grade 3/4 toxicities were collected using CTCAEv4.0. Acute (aGVHD) and chronic 
GVHD were scored using consensus criteria.16,17 For the purpose of this analysis, clinical 
high-risk disease at diagnosis was defined as being >2 years of age,11,13,18 platelets <40 × 
109/L,18 or having a hemoglobin F elevated for age.1,18 Biologic high-risk disease was 
defined as having any cytogenetic abnormality,2,13 secondary mutations,19 or DNA-
methylation designation of intermediate or high.20
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JMML Mutation Testing—All patients enrolled on ASCT1221 were sequenced to 
determine their JMML mutation status in real-time, using a CLIA-certified assay at 
diagnosis, pre-HCT, at defined time-points post-HCT, and at relapse (when applicable). The 
entire coding sequence of Ras-pathway genes including NF1, NRAS, KRAS, PTPN11 and 
CBL were analyzed and the allele fraction of each mutation was reported to the treating 
physician. All patients were analyzed on the Ion-Torrent platform using a tumor-normal 
approach to distinguish germline from somatic mutations, as described previously.21 Tumor 
samples were obtained from mononuclear cells from blood or bone marrow. Germline 
samples were obtained from buccal swabs or bone marrow fibroblasts.
UCSF500 Sequencing—After ASCT1221 was closed, our group reported on the 
presence of secondary mutations in 11 additional genes, including SETBP1, JAK3, ASXL1 
and SH2B3. Patients who were randomized and received a HCT on study had diagnostic 
material sequenced using the UCSF500 assay. This assay compares tumor to normal for 
approximately 500 genes that are commonly altered in cancer. Twelve of 15 transplanted 
patients had samples (buccal or bone marrow fibroblasts and relapse, when available) 
evaluated. Analysis and determination of pathogenic variants was performed, as previously 
described.21
Exome Sequencing—Three of 15 transplanted patients who had relapse samples 
available were analyzed using whole exome sequencing (WES) with a trio approach 
(normal-diagnosis-relapse). Analysis and determination of pathogenic variants and copy 
number were performed, as previously described.21,22
DNA Methylation Analysis—Fourteen of 15 transplanted patients had diagnostic tumor 
DNA available for genome-wide DNA methylation analysis performed using the Illumina 
450k BeadChip platform. Patient samples from ASCT1221 were compared to a cohort of 39 
distinct JMML patients, and using a “nearest centroid neighbor” approach were classified 
with a low, intermediate or high methylation-cluster designation, as previously described.20
Statistical Analysis
ASCT1221 was powered to accrue 54 patients in each arm in order to pick-the-winner of 
regimens, Arm A and Arm B in terms of TRM and EFS, with the outcome determined after 
all eligible patients had ≥18 months of follow-up, as patients with JMML rarely relapse >18 
months post-HCT.1,2 An interim analysis of outcomes at 2 years after the start of the study 
was planned to look at rates of graft failure, relapse, and TRM. Primary response measures 
were TRM, EFS, overall survival (OS), and relapse/disease progression as of June 30, 2017. 
The Kaplan-Meier method was used to estimate probabilities of EFS and OS. Events were 
defined as relapse/progression or TRM. The probabilities of relapse/progression, TRM, 
SOS, and GVHD were estimated using the method of cumulative incidence that accounts for 
competing events (i.e. death). The significance of observed differences in proportions was 
tested using the Fisher’s exact test. Clopper-Pearson was used to calculate confidence 
intervals. Comparison of median between arms was done using Wilcoxon rank-sum test. All 
tests were two-sided with P values <0.05 considered statistically significant.
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Thirty patients were enrolled, however 3 patients were determined to not meet diagnostic 
criteria for JMML (Supplemental Figure S1). The baseline characteristics of the remaining 
27 patients are listed in Table 1. No patient had evidence of neurofibromatosis type-1; 96.3% 
of patients had a canonical Ras-pathway mutation. High-risk disease was noted 
retrospectively in 15%, 19%, and 47% of patients based on the presence of cytogenetic 
abnormalities, secondary mutations, or DNA hypermethylation, respectively.2,13,19,20
One patient withdrew consent shortly after enrollment. Two patients (with KRAS p.G12D 
and KRAS p.G13D) were not eligible for Part 2 of the study due to progression to AML. 
Thus, 24 patients were eligible to proceed to HCT, of which 15 patients were randomized 
(Table 2). One patient (with PTPN11 p.E76K) refused HCT and died of progressive disease. 
Four patients (with NRAS p.G12D, CBL p.Y371H, CBL p.Y371splice_site, and without an 
identifiable mutation) were intentionally observed without HCT per physician preference, all 
without signs of progression at last follow-up. Four patients were treated with non-protocol 
HCT, three after randomization was suspended.
Baseline characteristics between Arm A (Bu-Cy-Mel) and Arm B (Bu-Flu) were notable for 
33% (2/6) of patients in Arm A retrospectively identified to have high-risk biological 
features compared to 67% (6/9) of patients in Arm B (p=0.31). In the 15 randomized 
patients, mutant allele burden was measured at the time of diagnosis and within 2 weeks of 
start of conditioning. As shown in Figure 1, the use of low-dose pre-HCT chemotherapy did 
not impact mutant allele burden compared to no chemotherapy, however, the two patients 
given AML-like chemotherapy achieved low mutant allele burdens (0 and 1.4%) upon count 
recovery. No patient underwent splenectomy prior to HCT.
HCT Toxicities & GVHD
Cumulative busulfan exposure was similar between the 2 arms (p=0.64). Day 100 TRM 
occurred in one patient (7% overall), who was assigned to Arm B. This patient had 
significant disease burden at time of HCT, and subsequently developed SOS and multi-
system organ failure on Day+12 post-HCT. In total, SOS developed in 50% (3/6) and 22% 
(2/9) of patients on Arms A and B, respectively (p=0.33). Other notable grade 3–4 toxicities 
that occurred prior to Day 100 included oral mucositis (33% in both Arms), and febrile 
neutropenia (33% in both Arms). No SOS or Grade 3–4 toxicities were reported in 2/6 
(33%) and 4/9 (44%) of patients in Arms A and Arm B, respectively.
Three patients developed Grade I aGVHD, while no patient developed Grade II aGVHD. 
The cumulative incidence of Grade III-IV aGVHD by 100 days was 27% (95% CI, 8–51%), 
with no difference between Arms (p=0.48). However, despite the presence of severe 
aGVHD, 3/4 patients eventually relapsed. Chronic GVHD occurred in only 1 patient total 
(in Arm A), for an 18-month cumulative incidence of 7% (95% CI, 0.33–28%).
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All patients had evidence of primary neutrophil recovery. One patient in Arm B had 
secondary graft loss (no detectable donor chimerism) in conjunction with JMML 
progression. For the other 13 patients, the median initial whole blood chimerism was 100% 
(range, 98–100%) for patients in Arm A, compared to 97% (range, 51–100%) in Arm B 
(p=0.03). Patient-level risk-characteristics and outcomes are shown in Table 3. The 
cumulative incidence of disease progression by 18-months was 17% (95% CI, 0.4–55%) and 
55% (95% CI, 16–83%) for patients on Arms A and B, respectively (p=0.19).
Two general patterns of disease progression were noted (Figure 2). Two patients (both in 
Arm B) entered HCT with large disease burdens (clinically and molecularly). Although both 
recovered neutrophils (and 1 had Grade III aGVHD), they also continued to have clinical 
and molecular signs of residual JMML and were scored as non-responders. Two patients 
(both in Arm B) appeared to be in clinical remission post-HCT, however, they continued to 
have low mutant allele burden (0.8–1.9%) measured at Day +30 post-HCT. Both eventually 
progressed clinically, with a corresponding increase in their molecular burden, and were 
scored as relapses. In contrast, nine patients had no evidence of mutant allele burden at Day 
+30 post-HCT, and only 2 of them (one in Arm A and 1 in Arm B) progressed (p=0.04).
Monosomy 7 was present at diagnosis in 13% (2/15) patients. Of the three relapsed patients 
who were analyzed using WES, two developed chromosome 7 derangements (Supplemental 
Figure S2). Neither had monosomy 7 detected (by FISH, conventional cytogenetics, nor 
WES) at diagnosis, implying that clonal evolution contributed to relapse in these patients.
Post-HCT Survival
The estimated 18-month post-HCT EFS of the entire cohort was 47% (95% CI, 21–69%), 
with a median follow-up time of 29 months (range, 13–44 months) in surviving patients. As 
shown in Figure 3, the estimated 18-month EFS was 83% (95% CI, 27–97%) and 22% (95% 
CI, 03–51%) in Arms A and B, respectively (p=0.04). When this imbalance in events 
became apparent, the Data and Safety Monitoring Committee suspended further 
randomization and ASCT1221 was closed. Patients who relapsed/progressed post-HCT were 
taken off-study and treated per physician-discretion. The estimated 18-month post-HCT OS 
was 64% (95% CI, 34–83%) overall, with 83% (95% CI, 27–97%) and 48% (95% CI, 12–
77%) in Arms A and B, respectively (p=0.26).
Patients with biological high-risk disease (classified retrospectively) had a similar 18-month 
EFS compared to standard-risk disease: 50% (95% CI, 15–77%) and 43% (95% CI, 10–
73%), respectively (p=0.41), though small numbers limits ASCT1221’s power to address 
this question. The 18-month EFS was 17% (95% CI, 0.77–52%) in patients not treated with 
any chemotherapy, 57% (17–84%) in patients who were given low-dose chemotherapy, and 
100% in the 2 patients treated with AML-like chemotherapy (p=0.08).
DISCUSSION
JMML is a rare disease of early childhood that is typically curable only with HCT. However, 
5-year EFS with current approaches remain sub-optimal, ranging from 39–53%.1,2 On 
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ASCT1221, we tested two conditioning regimens (busulfan-cyclophosphamide-melphalan 
versus busulfan-fludarabine) in a randomized fashion. While the overall 18-month EFS of 
47% was similar to that of other reported JMML HCT cohorts, ASCT1221 was suspended 
early for excessive events in the Bu-Flu arm.
Conclusions regarding the optimal conditioning regimen are limited by small numbers, 
possible imbalances in disease severity between the arms, and differing approaches to pre-
HCT chemotherapy; the latter two potentially having a substantial impact on post-HCT 
outcomes. Nevertheless, ASCT1221 is the first prospective trial wherein all transplanted 
patients were molecularly characterized and confirmed to have JMML, an important 
consideration given that there are known mimics of the disease, such as Wiskott-Aldrich 
Syndrome23 and Infantile Osteopetrosis.24
In regards to disease severity, to date a consensus risk-stratification system for patients with 
JMML is lacking. High-risk features that have been reported in some cohorts include older 
age,1,2,11,13,18 mutations in PTPN11,11,13 presence of monosomy 7 or other cytogenetic 
abnormalities,2,11,13 low platelet counts,18,19 elevated HgbF,1,18 increased blasts or an AML-
like gene-expression profile,1,13 DNA hyper-methylation,20,25,26 and the presence of >1 
somatic mutation in genes such as SETBP1, SH2B3, ASXL1, JAK3, and others.19,27,28 The 
exact weighting of these different factors in determining an overall risk-status is not yet 
known. ASCT1221 was designed to stratify only by PTPN11 status and donor type, and not 
on age or newer biologic risk-factors. Nevertheless, the better outcomes with the more 
intensive Bu-Cy-Mel supports the hypothesis that treatment-delivered remains an important 
prognostic factor, in that standard-risk patients may still relapse/progress if not adequately 
challenged with aggressive chemotherapy either pre-HCT or during conditioning.
Treating physicians were allowed to choose whether or not to administer any pre-HCT 
chemotherapy, therefore patients presented to HCT with markedly-different disease burdens. 
We noted that the use of 6-MP, while capable of reducing some of the clinical symptoms, 
had minimal effect on mutant allele burden, supporting in vitro data that JMML myeloid 
progenitors are often resistant to 6-MP.29 Some patients were not treated with any 
chemotherapy pre-HCT, on the basis of the EWOG-MDS/EBMT study results that patients 
who received either no therapy or low-dose chemotherapy compared to AML-like 
chemotherapy had nearly-identical 5-year EFS, relapse, and TRM on univariate analysis.1 
However, since the choice of pre-HCT chemotherapy in the EWOG-MDS/EBMT study was 
left to the treating physician’s discretion, patients with more aggressive disease may have 
been more intensively pre-treated. Furthermore, the EWOG-MDS/EBMT study included 
10% of patients with AML transformed out of JMML, which had 0% 5-year EFS. It is 
possible that inclusion of these very high-risk patients (who may have received AML-like 
chemotherapy) might have obscured a potential benefit to intensive chemotherapy in a 
“standard” patient with JMML. In the 2013 EUROCORD/CIBMTR retrospective UCB 
study (excluding patients with >20% blasts) there was improved EFS in patients who 
received AML-like therapy compared to none or low-dose chemotherapy (55% vs. 32%; 
p=0.048).2 COG AAML0122 evaluated the efficacy of a pre-transplant window therapy with 
a farnesyl transferase inhibitor followed by two cycles of intensive AML-type chemotherapy 
using fludarabine and cytarabine.30 For patients who achieved a complete response (defined 
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as normalization of WBC count and resolution of organomegaly) there was a trend towards 
improved 5-year EFS (54% vs. 33%, p=0.144) and 5-year relapse rate (38% vs. 57%, 
p=0.154); though AAML0122 was not powered to address this question. The Japanese 
Pediatric MDS Study Group’s JMML HCT report included three patients who received 
AML-like chemotherapy prior to HCT; all remained relapse-free.7 The European community 
is currently testing the potential role of azacytidine in decreasing pre-HCT disease burden 
with the goal of improving post-HCT outcomes.31,32
An established principle of pediatric allogeneic HCT for hematologic malignancies is that 
patients who come to HCT with lower disease burden have improved post-HCT outcomes, 
typically due to lower relapse rates. Therefore, for acute lymphoblastic leukemia,33 AML,34 
and myelodysplastic syndrome with excess blasts,35–38 pre-HCT chemotherapy aiming to 
achieve the best possible remission status is considered standard-of-care. This also holds for 
the adult JMML-like disease chronic myelomonocytic leukemia.39 One potential explanation 
may be that the alloreactive graft-versus-leukemia (GVL) effect is typically incapable of 
controlling large disease burdens.40 Although the numbers were small, we noted that all 
patients who developed GVHD (a surrogate for GVL) on the intensive Arm A (Bu-Cy-Mel) 
remained disease-free at 18 months, while all patients on Arm B (Bu-Flu) who developed 
GVHD still relapsed. As such, the more intensive Bu-Cy-Mel regimen may be required to 
provide optimal de-bulking when patients present to HCT with large disease burdens. 
Conversely, the less-intensive Bu-Flu regimen, or other less-toxic regimens, may still be a 
potential option for patients who receive effective pre-HCT chemotherapy, with the caveat 
that our numbers are too small to make any definitive conclusions. Finally, we did not test 
the regimen which adds Melphalan to Busulfan and Fludarabine, and this could potentially 
be as efficacious as Bu-Cy-Mel.7
Finally, the particular Bu-Flu regimen used on ASCT1221 administered busulfan and 
fludarabine on separate days. However, in vitro data suggests improved killing of AML cells 
when the two are administered together.41 In addition, the patients on the Bu-Flu arm had a 
low cumulative busulfan exposure (median 68 mg×h/L) compared to the recently-identified 
optimal AUC of 78–101 mg×h/L when using a single alkylator,9 which also may have 
contributed to poor outcomes in this group. Despite these modest busulfan levels, SOS rates 
were high in both Arms, suggesting that JMML patients may need additional SOS 
prophylaxis.
In conclusion, JMML patients with high pre-HCT disease burden have a poor outcome when 
treated with a conditioning regimen of busulfan-fludarabine. Advances in molecular testing 
now allow better characterization of pre-HCT responses to chemotherapy. In addition, 
improved understanding of precise pre-HCT risk-stratification will potentially facilitate 
future risk-adapted treatment approaches. Further efforts at studying novel approaches to 
improving the outcomes of rare patients with JMML will likely require international 
cooperation, as well as detailed molecular risk-profiling to ensure that comparisons between 
regimens are valid.
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TABLE 1
Clinical and Molecular Characteristics at Time of Diagnosis for Eligible Patients
Total Enrolled 27
Male Sex 17 (63%)
Median Age at Diagnosis (range) 13.3 months (0.7–148 months)
Splenomegaly at Diagnosis 24 (89%)
Median WBC Count, × 109/L (range) 26.9 (7–122)
Median Absolute Monocyte Count, × 106/L(range) 4430 (1120–96,000)
Median Platelet Count, × 109/L (range) 46 (10–227)
Median Peripheral Blood Blasts (range) 2% (0–13%)
Median Bone Marrow Blasts (range) 3% (0–16%)
Median Hemoglobin F (range) 8% (1–66%)
RAS-Pathway Mutation Identified
 PTPN11 11 (41%)p.E76K (N=8); p.E76G (N=1); p.D61Y (N=1); p.E69K (N=1);
 KRAS 6 (22%)p.G13D (N=3); p.G13Y (N=1); p.G12D (N=1); p.G12V (N=1)
 NRAS 3 (11%)p.G12D (N=2); p.G13D (N=1)
 RRAS 1 (4%)p.Q87L (N=1)
 RRAS2 1 (4%)p.Q72L (N=1)
 CBL 4 (15%)p.C404R (N=1); p.Y371H (N=1); pY371splice_site (N=1);
 None 1 (4%)
Median Mutant Allele Burden (range)* 43.5% (8.1–50.2%)
Cytogenetic Abnormality
 Monosomy 7 3 (11%)
 Other [t(3;5)] 1 (4%)
 None 23 (85%)
Secondary Mutations 5 (19%)
DNA Hypermethylation (Transplanted Patients Only)
  Low 7 (47%)
  Intermediate 4 (27%)
  High 3 (20%)
  Not Available 1 (6%)
Median IgG, mg/dL (range) 1045 (15–2990)
Direct Antibody Test (Coomb’s) Positive 5/23 (22%)
 Elevated IgG for Age or DAT Positive 5/11 (46%) with RAS mutation;
7/16 (44%) without RAS mutation
*
For patients with mutations in PTPN11, KRAS, NRAS, or RRAS
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TABLE 2
Risk and Transplant Characteristics by Treatment Assignment
Risk Factors & HCT Characteristics Arm A: Busulfan-Cyclophosphamide-Melphalan (N = 6) Arm B: Busulfan-Fludarabine (N = 9)
High-Risk Clinicallyˆ 3 (50%) 7 (78%)
 Age >2 years at Diagnosis 1 (16%) 4 (44%)
 Platelets <40 × 109/L at Diagnosis 2 (33%) 4 (44%)
 Hemoglobin F elevated for age 2 (33%) 6 (67%)
High-Risk Biologically* 2 (33%) 6 (67%)
 Cytogenetic Abnormality 1 (16%) 2 (22%)
 Secondary Mutations 1 (16%) 3 (33%)
 DNA Methylation (Intermediate or High) 2 (33%) 5 (63%)1




 None 2 (66%) 4 (45%)
 Low-Dose 4 (67%) 3 (33%)
 AML-Like 0 2 (22%)
Median Pre-HCT Allele Burden (range) 39.4% (23%-46.8%) 46.9% (0–50.3%)
Donor
 HLA-Matched Related 2 (33%) 3 (33%)
 8/8 HLA-Matched Unrelated 3 (50%) 5 (56%)
 <8/8 HLA-Mismatched Unrelated 1 (16%) 1 (11%)
Stem Cell Source
 Bone Marrow 6 (100%) 7 (78%)
 Peripheral Blood 0 1 (11%)
 Umbilical Cord Blood 0 1 (11%)
Busulfan Cumulative AUC (mg*h/L) 71 (58–87) 68 (62–80)
ˆ
Defined as the presence of at least 1 of the following: a) age >2 years at diagnosis; b) platelets <40 × 109/L at diagnosis; c) hemoglobin F elevated 
for age
*
Defined as presence of at least 1 of the following: a) cytogenetic abnormality; b) secondary mutation; or c) DNA Methylation Intermediate or 
High
1
Of 8 patients tested
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